In a report released today, Graig Suvannavejh from Mizuho Securities reiterated a Buy rating on EyePoint Pharmaceuticals, with a price target of $28.00. The company’s shares opened today at $12.92.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Suvannavejh is a 4-star analyst with an average return of 5.5% and a 48.05% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Harmony Biosciences Holdings, and Terns Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for EyePoint Pharmaceuticals with a $33.00 average price target.
Based on EyePoint Pharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $5.33 million and a GAAP net loss of $59.43 million. In comparison, last year the company earned a revenue of $9.48 million and had a GAAP net loss of $30.83 million
Read More on EYPT:
Disclaimer & DisclosureReport an Issue
- EyePoint reports inducement grants under NASDAQ listing rule
- EyePoint Pharmaceuticals Completes Promising Study on EYP-1901 for Diabetic Retinopathy
- EyePoint price target raised to $28 from $26 at Mizuho
- EyePoint Pharma’s Earnings Call: Clinical Wins Amid Financial Challenges
- EyePoint Pharma Advances DURAVYU Trials Amid Financial Challenges
/Super%20Micro%20Computer%20Inc%20logo%20on%20building-by%20Poetra_RH%20via%20Shutterstock.jpg)
/Nvidia%20logo%20and%20sign%20on%20headquarters%20by%20Michael%20Vi%20via%20Shutterstock.jpg)
